Trial Profile
Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal Trial With Tadekinig Alfa (r-hIL-18BP) in Patients With IL-18 Driven Monogenic Autoinflammatory Conditions: NLRC4 Mutation and XIAP Deficiency
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Feb 2024
Price :
$35
*
At a glance
- Drugs Tadekinig alfa (Primary)
- Indications Autoimmune disorders
- Focus Registrational; Therapeutic Use
- Sponsors AB2 Bio
- 01 Feb 2024 Status changed from active, no longer recruiting to completed.
- 26 Nov 2023 This trial has been completed in Germany (End Date; 31 Oct 2023), according to European Clinical Trials Database record.
- 20 Jul 2023 Planned End Date changed from 30 Jul 2023 to 31 Oct 2023.